Abstract: The invention relates to transdermal therapeutic systems (TTS) which include, as active ingredient, the NMDA receptor antagonist memantine or one of its physiologically compatible salts. The TTSs can be produced and used for treating diseases of the central nervous system.
Inventors:
René Eifler, Michael Horstmann, Regine Kaufmann, Patrick Mohr, Eric Galia, Wolfgang Prange, Stefan Buller, Klaus Pusecker, Jan Stampfuss, Susanne Stoelben
Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.
Type:
Grant
Filed:
May 17, 2018
Date of Patent:
July 16, 2019
Assignees:
UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AG
Inventors:
Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller
Abstract: The invention relates to a medical product for a fastening duration of at least 7 days having good skin compatibility. The medical product includes a central adhesive compartment (3) and an over-patch. The over-patch is free of active ingredients and is formed from a water-vapor-permeable back layer (1) and an adhesive polymer layer (2) that is free of active ingredients. The invention further relates to a method for the production of the foregoing medical product, and to kits of parts containing laminates of layers 1 and 2.
Type:
Grant
Filed:
March 16, 2015
Date of Patent:
July 2, 2019
Assignee:
LTS Lohmann Therapie-Systeme AG
Inventors:
Gerhard Ritzdorf, Thomas Hille, Petra Botzem, Gabriel Wauer, Marlene Fuhrmann
Abstract: The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and characterized by a considerably increased utilization of the active substance.
Type:
Application
Filed:
February 28, 2019
Publication date:
June 27, 2019
Applicant:
LTS LOHMANN THERAPIE-SYSTEME AG
Inventors:
Thomas Hille, Michael Horstmann, Walter Mueller
Abstract: A substantially solvent-free matrix layer containing (?)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol is produced by adding an active substance to an adhesive solution, coating the resultant active substance-containing adhesive solution onto a suitable sheet, and removing the solvents in a drying process to give said substantially solvent-free matrix layer.
Type:
Grant
Filed:
September 7, 2004
Date of Patent:
June 18, 2019
Assignees:
UCB BIOPHARMA SPRL, LTS LOHMANN THERAPIE-SYSTEME AG
Abstract: The present invention relates to an oral film consisting essentially of dexamethasone and hydroxypropyl methylcellulose, wherein the concentration of dexamethasone is 30% w/w or more and the concentration of hydroxypropyl methylcellulose is between 35 and 70% w/w based on total dry matter.
Type:
Application
Filed:
December 7, 2018
Publication date:
June 13, 2019
Applicants:
ACUCORT AB, LTS LOHMANN THERAPIE-SYSTEME AG
Abstract: A device with a positioning frame which can be adhered onto the skin and with a transdermal therapeutic system which can be inserted into a cut-out that passes through the positioning frame. The active substance dispensing outlet side of the inserted transdermal therapeutic system facing the skin. The device includes a tool unit which can be inserted into the cut-out of the positioning frame and centered in said cut-out in order to produce openings at least in the uppermost layer of the skin.
Type:
Grant
Filed:
December 24, 2015
Date of Patent:
June 11, 2019
Assignee:
LTS LOHMANN THERAPIE-SYSTEME AG
Inventors:
Uwe Wortmann, Roman Hadaschik, Michael Horstmann
Abstract: The invention relates to a transdermal therapeutic system, preferably a transdermal patch, having an active ingredient-containing matrix formed substantially of a water-insoluble base material, such as rubber and synthetic polymers, into which is incorporated water-soluble and/or water-swellable inclusion bodies, e.g. inclusion bodies formed from polyvinyl alcohol or polyethylene glycol, that further include micronized or nanoscale active ingredient particles.
Type:
Grant
Filed:
May 30, 2007
Date of Patent:
May 21, 2019
Assignee:
LTS Lohmann Therapie-Systeme AG
Inventors:
Michael Horstmann, Mohammad Sameti, Tobias Jung
Abstract: A substantially solvent-free matrix layer containing (?)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol is produced by adding an active substance to an adhesive solution, coating the resultant active substance-containing adhesive solution onto a suitable sheet, and removing the solvents in a drying process to give said substantially solvent-free matrix layer.
Abstract: A device for dispensing active ingredient-containing or active ingredient-carrying strips, including a housing in which a coil chamber for receiving an active ingredient-containing or active ingredient-carrying band is arranged, in which a gear transmission with a driven roller for conveying the band is mounted, and in which a separating device for separating the strips from the band is arranged. A method for dispensing active ingredient-containing or active ingredient carrying strips using such a device is also disclosed. An active ingredient-containing or active ingredient-carrying band is arranged between the driven roller and the pressure roller. A shift clutch transmission having a manually actuatable trigger element is arranged upstream of the gear transmission. The driven roller can be driven in incremental strips by the shift clutch transmission. A device and method is disclosed for dispensing active ingredient-containing or active ingredient-carrying strips with a largely equal dosage are developed.
Type:
Application
Filed:
October 17, 2018
Publication date:
February 14, 2019
Applicant:
LTS LOHMANN THERAPIE-SYSTEME AG
Inventors:
MARC BLOMENKEMPER, MICHAEL LINN, RONALD HACKBARTH, MARKUS BEE
Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.
Type:
Grant
Filed:
January 31, 2018
Date of Patent:
November 20, 2018
Assignees:
UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AG
Inventors:
Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller
Abstract: Disclosed is a method for marking film-type dosage forms, comprising at least the positioning of a film-type dosage form between two layers of a scalable packaging material, the sectional heat-scaling of the two layers of the scalable packaging material so as to obtain an edge-sealed bag containing the film-type dosage form, and the blind-embossing of the film-type dosage form contained in the edge-sealed bag through at least one of the two layers of packaging material of the edge-sealed bag.
Type:
Application
Filed:
October 28, 2016
Publication date:
November 1, 2018
Applicant:
LTS Lohmann Therapie-Systeme AG
Inventors:
Petra Botzem, Torsten Grunenberg, Thomas Hille, Peter Steinborn
Abstract: A microneedle system and method for production thereof. From a board a web grating is produced which has a plurality of grating nodes each defined by three apertures and which has web grating wedges. The microneedle system comprising a board and a plurality of openings delimited circumferentially by a web grating, having at each opening at least one web grating wedge having a needle-shaped tip which projects from the board and which is oriented at least approximately normal to the board. Web grating wedges having needle-shaped tips protrude into each aperture from at least three different directions. In order to produce openings, at least all the web grating wedges which protrude into an aperture are bent by a punch and the needle-shaped tips thereof are oriented normal to the plane of the web grating. At least two web grating wedges are arranged at each opening.
Abstract: Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.
Type:
Application
Filed:
June 15, 2018
Publication date:
October 11, 2018
Applicant:
LTS Lohmann Therapie-Systeme AG
Inventors:
Wolfgang Laux, Beatrix Platt, Nico Reum
Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.
Type:
Application
Filed:
May 17, 2018
Publication date:
September 20, 2018
Applicants:
UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AG
Inventors:
Hans-Michael WOLFF, Christoph ARTH, Luc QUERE, Walter MÜLLER
Abstract: Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.
Type:
Grant
Filed:
July 3, 2014
Date of Patent:
August 14, 2018
Assignee:
LTS Lohmann Therapie-Systeme, AG
Inventors:
Wolfgang Laux, Beatrix Platt, Nico Reum
Abstract: Transdermal therapeutic system for the transdermal administration of a systemically active agent comprising a self-adhesive layer structure, comprising A) a backing layer, and B) a dried biphasic layer, the dried biphasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and b) an inner phase having a composition comprising at least one active agent, wherein the inner phase forms dispersed deposits in the outer phase, and c) 0.1% to 3.5% of an interface mediator with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C., and and C) optionally an additional skin contact layer.
Abstract: Monolayered or multilayered, film-shaped, pressure-sensitive adhesive preparations for application in the oral region and a process for manufacturing such preparations. The preparations contain at least one polymethyl vinyl ether-maleic acid anhydride copolymer, polyvinyl acetate and/or at least one copolymer of the polyvinyl acetate with vinyl alcohol esters of fatty acids, as well as at least one cosmetic and/or pharmaceutical active substance.
Abstract: The invention generally relates to a transdermal therapeutic system which comprises a backing layer, an adhesive layer, a polymer layer and a removable protective layer. The adhesive layer is an organosiloxane layer that is anchored to the backing layer by siliconization.
Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.
Type:
Application
Filed:
January 31, 2018
Publication date:
May 31, 2018
Applicants:
UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AG
Inventors:
Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller